_edited.png)
Indian pharma companies pivot to US biosimilars market as USFDA eases regulations
Indian drugmakers are accelerating their biosimilars plans after the USFDA released draft guidelines simplifying regulatory pathways. With the US biosimilars market expected to surge from $22.6 billion in 2025 to over $90 billion by 2034, several Indian pharma companies are exploring new launches, partnerships, and even acquisitions to fast-track entry.
By Finblage Editorial Desk
5:54 pm
3 December 2025
Sources & Disclaimer
This article is compiled from publicly available information, including company disclosures, stock exchange filings, regulatory announcements, and reports from global and domestic financial publications. The content has been editorially reviewed and enhanced by the Finblage Editorial Desk for clarity and investor awareness purposes only.
All information provided on Finblage is strictly for educational and informational use and should not be considered as financial, investment, legal, or professional advice. Readers are advised to conduct their own independent research and consult a certified financial advisor before making any investment decisions. Finblage shall not be held responsible for any losses arising from the use of information published on this website.
Premium Edition
Insights > War & Aviation Industry
How the Iran War Is Sending Airline Costs Into Turbulence
For airlines, where fuel accounts for up to 40% of operating costs, the consequences have been immediate and severe: tens of thousands of cancelled flights, emergency fuel surcharges, surging ticket prices, and sharp stock market declines. Carriers across Asia, Europe, and North America are scrambling to manage the shock, with the divide between hedged....
13 March 2026
